J Liver Cancer.  2016 Mar;16(1):57-62. 10.17998/jlc.2016.16.1.57.

Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib

• Kim DH
• Min GH
• Lee DW
• Ahn KR
• Kim JH
• Suh SJ
• Jung YK
• Yim HJ

• KMID: 2198525
• DOI: http://doi.org/10.17998/jlc.2016.16.1.57

Abstract

Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.

Keyword

Carcinoma, Hepatocellular; Drug therapy; Sorafenib; Treatment outcome

MeSH Terms

Carcinoma, Hepatocellular*
Drug Therapy
Humans
Lung*
Neoplasm Metastasis*
Phosphotransferases
Protein-Tyrosine Kinases
Receptors, Vascular Endothelial Growth Factor
Treatment Outcome
Venous Thrombosis
Phosphotransferases
Protein-Tyrosine Kinases
Receptors, Vascular Endothelial Growth Factor